(Bloomberg) -- Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its chief executive officer said in an interview. Lilly’s drug, ...
StockStory.org on MSN
The 5 most interesting analyst questions from Biogen’s Q4 earnings call
Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non ...
The Food and Drug Administration on Monday approved Biogen's Alzheimer's disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living ...
With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage ...
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results